Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Chief Medical Officer | May 13, 2022 | May 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date May 13, 2022 · Filed May 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
After 2022-05-13 transaction · row 1
1 source rowRow 1 · 2022-05-13 · Purchase · Acquired 6,000 · Balance 6,000 F1: Purchase price was 1.65 Euros per share which was converted into dollars using the noon buying rate of 1.00 Euro to $1.03745 based on information provided on May 13, 2022 via Xignite. |
Filing footnotes · ownership attribution and instrument terms
F1: Purchase price was 1.65 Euros per share which was converted into dollars using the noon buying rate of 1.00 Euro to $1.03745 based on information provided on May 13, 2022 via Xignite.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2022 Filed May 16, 2022 20:19 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | PurchaseCommon Stock | 6,000 | $1.71 | $10,260.00 |
DisclosureSEC source: 0001583648-22-000030 · wf-form4_165274672969009.xml · nonDerivative · entry 1 Demuth Tim · CIK 0001875267 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · price: Purchase price was 1.65 Euros per share which was converted into dollars using the noon buying rate of 1.00 Euro to $1.03745 based on information provided on May 13, 2022 via Xignite. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 16:50 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (Right to buy) · Derivative | 100,000 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001562180-22-001876 · primarydocument.xml · derivative · entry 1 Demuth Tim · CIK 0001875267 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on February 22, 2023 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 16:19 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 360,000 | $0.00 Strike: $3.48 | $0.00 |
DisclosureSEC source: 0001562180-21-005129 · primarydocument.xml · derivative · entry 1 Demuth Tim · CIK 0001875267 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2031-08-01 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on August 1, 2022 and vests as to an additional 6.25% of the option shares at the end of each successive calendar quarter thereafter beginning on December 31, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.